TWI363625B - Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases - Google Patents

Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases Download PDF

Info

Publication number
TWI363625B
TWI363625B TW094117334A TW94117334A TWI363625B TW I363625 B TWI363625 B TW I363625B TW 094117334 A TW094117334 A TW 094117334A TW 94117334 A TW94117334 A TW 94117334A TW I363625 B TWI363625 B TW I363625B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
phenyl
formula
base
Prior art date
Application number
TW094117334A
Other languages
English (en)
Chinese (zh)
Other versions
TW200608974A (en
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Gestel Jozef Frans Elisabetha Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI363625(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200608974A publication Critical patent/TW200608974A/zh
Application granted granted Critical
Publication of TWI363625B publication Critical patent/TWI363625B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094117334A 2004-05-28 2005-05-27 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases TWI363625B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28

Publications (2)

Publication Number Publication Date
TW200608974A TW200608974A (en) 2006-03-16
TWI363625B true TWI363625B (en) 2012-05-11

Family

ID=34929150

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094117334A TWI363625B (en) 2004-05-28 2005-05-27 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Country Status (34)

Country Link
US (2) US20070249667A1 (enExample)
EP (1) EP1753427B1 (enExample)
JP (2) JP5081617B2 (enExample)
KR (2) KR20130024969A (enExample)
CN (2) CN1976704B (enExample)
AP (1) AP2037A (enExample)
AR (1) AR049127A1 (enExample)
AT (1) ATE390925T1 (enExample)
AU (1) AU2005249231B2 (enExample)
BR (1) BRPI0510414B1 (enExample)
CA (1) CA2566544C (enExample)
CL (1) CL2009001980A1 (enExample)
CY (1) CY1110388T1 (enExample)
DE (1) DE602005005810T2 (enExample)
DK (1) DK1753427T3 (enExample)
EA (1) EA010651B1 (enExample)
ES (1) ES2306146T3 (enExample)
HR (1) HRP20080307T3 (enExample)
IL (1) IL179630A (enExample)
JO (1) JO2524B1 (enExample)
ME (1) ME01105B (enExample)
MX (1) MXPA06013888A (enExample)
MY (1) MY140611A (enExample)
NO (1) NO338624B1 (enExample)
NZ (1) NZ550840A (enExample)
PA (1) PA8635201A1 (enExample)
PL (1) PL1753427T3 (enExample)
PT (1) PT1753427E (enExample)
RS (1) RS50585B (enExample)
SI (1) SI1753427T1 (enExample)
TW (1) TWI363625B (enExample)
UA (1) UA90267C2 (enExample)
WO (1) WO2005117875A1 (enExample)
ZA (1) ZA200609899B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
CA2612614C (en) * 2005-06-28 2017-07-25 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
AU2010292148A1 (en) * 2009-09-11 2012-04-12 Vertex Pharmaceuticals Incorporated Compositions of N-benzyl-3-(4-chlorophenyl)-2- [methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-N- [3-(4-pyridyl)-1-[2-[4-pyridyl)ethy]propyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110366B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CA2954872C (en) * 2014-07-14 2019-08-13 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN114129526A (zh) 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
EP3677687A4 (en) * 2017-09-01 2021-05-26 The Kitasato Institute NEW COMPOSITION WITH THERAPEUTIC EFFECT AGAINST INFECTIONS DUE TO THE MYCOBACTERIUM-AVIUM COMPLEX AND THE PROCESS FOR THEIR PRODUCTION
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
CN115380029B (zh) * 2019-11-26 2025-06-17 南洋理工大学 用于治疗结核病的化合物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
CN117050006B (zh) * 2022-05-13 2026-02-13 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
AU2023382389A1 (en) * 2022-11-15 2025-05-15 Eli Lilly And Company Ahr agonists
CN121941498A (zh) 2023-09-28 2026-04-28 詹森药业有限公司 用于治疗非结核分枝杆菌的atp合酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
PT1527050E (pt) * 2002-07-25 2010-06-22 Janssen Pharmaceutica Nv Derivados de quinolina e sua utilização como inibidores de micobactérias
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
CY1110388T1 (el) 2015-04-29
JP2012229239A (ja) 2012-11-22
US20100168133A1 (en) 2010-07-01
IL179630A (en) 2011-05-31
JP2008500992A (ja) 2008-01-17
JP5675718B2 (ja) 2015-02-25
BRPI0510414A (pt) 2007-10-23
ES2306146T3 (es) 2008-11-01
EA010651B1 (ru) 2008-10-30
DE602005005810D1 (de) 2008-05-15
KR101371653B1 (ko) 2014-03-07
DK1753427T3 (da) 2008-07-21
NO20066041L (no) 2007-02-27
IL179630A0 (en) 2007-07-04
WO2005117875A1 (en) 2005-12-15
AP2006003828A0 (en) 2006-12-31
CN1976704A (zh) 2007-06-06
JO2524B1 (en) 2010-03-17
NO338624B1 (no) 2016-09-19
UA90267C2 (ru) 2010-04-26
CN102908347A (zh) 2013-02-06
EP1753427A1 (en) 2007-02-21
TW200608974A (en) 2006-03-16
AU2005249231A1 (en) 2005-12-15
DE602005005810T2 (de) 2009-04-09
KR20130024969A (ko) 2013-03-08
ME01105B (me) 2013-03-20
ZA200609899B (en) 2009-01-28
SI1753427T1 (sl) 2008-10-31
NZ550840A (en) 2010-01-29
AP2037A (en) 2009-10-09
BRPI0510414B1 (pt) 2022-04-05
HK1106136A1 (en) 2008-03-07
MY140611A (en) 2009-12-31
US20070249667A1 (en) 2007-10-25
AR049127A1 (es) 2006-06-28
EA200602260A1 (ru) 2007-04-27
KR20070017393A (ko) 2007-02-09
RS50585B (sr) 2010-05-07
PT1753427E (pt) 2008-07-04
MXPA06013888A (es) 2007-01-26
EP1753427B1 (en) 2008-04-02
CN1976704B (zh) 2012-12-05
PA8635201A1 (es) 2006-05-16
PL1753427T3 (pl) 2008-09-30
CA2566544C (en) 2012-04-17
ATE390925T1 (de) 2008-04-15
CL2009001980A1 (es) 2010-04-16
AU2005249231B2 (en) 2010-11-11
CA2566544A1 (en) 2005-12-15
HRP20080307T3 (hr) 2008-07-31
JP5081617B2 (ja) 2012-11-28

Similar Documents

Publication Publication Date Title
JP5675718B2 (ja) 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
CN103142595B (zh) 用于治疗潜伏性结核的喹啉衍生物
TWI323730B (en) Novel mycobacterial inhibitors
CN104812394B (zh) 吩噻嗪衍生物及其治疗肺结核的用途
JP2000256194A (ja) 核内レセプタ作動薬およびその効果増強剤
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
CN103313982B (zh) 苯基-异噁唑衍生物及其制备方法
JP6426530B2 (ja) 潜伏性結核の処置
CA2624497C (en) Antituberculosis drug combination comprising oxazole compounds
TWI427065B (zh) 抗菌之喹啉衍生物
JPH07504890A (ja) Nmda拮抗剤の相乗効果
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
TW200800183A (en) Quinoline derivatives as antibacterial agents
KR20210028339A (ko) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
WO2005102331A1 (ja) 骨粗鬆症治療剤
HK1177427A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤
HK1106136B (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HK1186125B (en) Quinoline derivatives for the treatment of latent tuberculosis

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent